CAP29 is a retrospective observational multicenter study conducted in 6 French centers. Patients were included if they were at least 18 years of age, with confirmed advanced (stage III not eligible to surgery or radiotherapy and stage IV) non-squamous NSCLC and if they did not receive any previous systemic anti-cancer treatment for metastatic disease. Exclusion criteria were: uncontrolled autoimmune disease, active infection (Hepatitis B, C, HIV), organ or bone marrow transplant, contraindication to ICI or to carboplatin/pemetrexed, incapacity to give informed consent or refusal to participate, patients with activating EGFR mutation or ALK and ROS translocations.
Patients were first identified via CHIMIO® software database. Then, they were recruited at time of first visit in Oncology Department. They had to give a non-opposition agreement before enrollment.
Patients were first identified via CHIMIO® software database. Then, they were recruited at time of first visit in Oncology Department. They had to give a non-opposition agreement before enrollment.
